12月29日，A股三大指数早盘冲高回落，午后震荡走低，截止收盘，沪指涨0.04%报3965.28点，连续九 日走高，深成指跌0.49%报13537.1点，创业板指跌0.66%报3222.61点，科创50指数涨0.04%报1346.32 点；沪深两市成交额2.14万亿，全市场超3300只个股下跌。 脑机接口概念表现活跃，海格通信、喜临门等涨停，翔宇医疗、麦澜德、三博脑科、创新医疗等跟涨。 消息面上，12月28日，第五届脑科学前沿与产业大会暨2025深圳脑机接口博览会启幕，"粤港澳大湾区 脑科学与中枢神经疾病AI创新联盟"正式启动。 盘面上，机器人概念午后反复活跃，上纬新材、步科股份20cm涨停创历史新高，五洲新春、模塑科技 等多股涨停。商业航天概念延续强势，神剑股份8连板，金风科技、雷科防务等十余股涨停。碳纤维概 念表现活跃，吉林化纤、和顺科技双双涨停；锂矿概念下挫，欣旺达跌逾11%；医药商业板块走弱，漱 玉平民跌超18%；氟化工板块回调，漱玉平民跌逾8%；电池概念午后震荡下挫，华盛锂电跌超7%；电 力板块持续走弱，国电电力跌近8%。 热点板块 商业航天概念延续强势 商业航天概念延续强势，10余只成分股涨停，神 ...

连板股方面，百大集团、*ST宁科6连板，胜通能源5连板，皮阿诺4连板，钧达股份、九牧王等5天3 板，皇氏集团4天3板，浙江世宝、利群股份等3连板，ST中迪4天2板，中央商场、威帝股份3天2板，长 飞光纤、立达信等2连板，西部材料、博纳影业等涨停。 *ST奥维连续7日跌停，*ST华嵘、*ST返利等跌停。 12月18日，A股全天下来共有73只涨停股、8只跌停股。医药商业概念活跃，重药控股7天4板，鹭燕医 药2连板，华人健康、一心堂等涨停；卫星互联网概念走强，*ST铖昌10天9板，盛洋科技2连板，顺灏 股份、北摩高科等涨停；AI医疗概念上涨，美年健康2连板，嘉和美康涨停。 ...

格隆汇12月18日｜A股三大指数涨跌不一，截至午间收盘，沪指涨0.16%报3876.4点，深证成指跌 0.85%，创业板指跌1.81%，北证50涨0.64%。全市场成交额10592亿元，较上日成交额放量190亿元，超 3600股上涨。盘面上，商业航天概念股爆发，医药商业、军工装备、IP经济板块涨幅居前；元件、海 南、电池板块走低。中金公司正在筹划吸收合并东兴证券(601198)、信达证券，东兴证券涨停，中金涨 超5%，信达证券涨4.55%。 | 上证指数 | | | | | 深证成指 | | | 创业板指 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | -3876.40 | | | | | ·13111.78 | | | -3118.30 | | | | +6.12 +0.16% | | | | | -112.73 -0.85% | | | -57.6 -1.81% | | | | 市场概况 66.33%用户看涨 > | | | | | | | | | | | | | | | | | 2619 | | | ...

记者丨金珊 孙永乐 编辑丨黎雨桐 视频 丨 陈泽锴 12月18日，A股三大指数涨跌不一，截至午间收盘，沪指拉升翻红，创业板指跌近2%。沪深两市半日成交额1.05万亿元，较上个交易日放量 192亿元，全市场超3600只个股上涨。 板块方面，医药商业、商业航天等涨幅居前，电池、证券等跌幅居前。 今日早盘，商业航天概念走势强劲，中国卫星、 北摩高科、西部材料、天箭科技等多股涨停 。航天环宇、邵阳液压、西测测试等涨超10%。 消息面上，由中国航天科技集团八院抓总研制的长征十二号甲可重复使用运载火箭，计划于2025年12月中下旬在酒泉卫星发射中心执行其历史 性的首次发射任务。 北摩高科 002985 融 30.65 +10.01% +8.46% 首板 | 最终涨停 10:33 盛洋科技 15.49 +10.01% +19.34% | | | 商业航天 ① 2092.74 2.49% | | 100 | | --- | --- | --- | --- | --- | | 成分股 | 基金 | 资金 | 分析 | 新闻 简况(F10) | | 名称/代码 | | 最新 ◆ | | 涨幅 = 5日涨幅 = > | | 神剑股 ...

| 上证指数 | 3831.53 | +6.72 | +0.18% | | --- | --- | --- | --- | | 000001 | | | | | 创业板指 | 3114.15 | +42.39 | +1.38% | | 399006 | | | | | 深证成指 | 13026.87 | +112.20 | +0.87% | | 399001 | | | | | श्रीलिप | 1303.84 | +10.46 | +0.81% | | 000688 | | | | | 北证50 | 1435.51 | -4.14 | -0.29% | | 899050 | | | | | 沪深300 | 4519.39 | +21.83 | +0.49% | | 000300 | | | | | 上证50 | 2958.24 | +3.46 | +0.12% | | 000016 | | | | 格隆汇12月17日｜A股主要指数走强，创业板指涨1.38%，沪指涨0.18%，深成指涨0.87%。算力硬件、 锂电、医药商业等方向涨幅居前，沪深京三市上涨个股近2900只。 ...

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Views - The report highlights a rapid increase in influenza-like illness (ILI) cases, suggesting that related detection and treatment products are expected to see significant growth. Recent data from the National Influenza Center indicates that the ILI percentage in southern provinces is 5.5%, up from 4.6% the previous week, and higher than the same period in 2022 and 2024 [5][14]. - The report emphasizes the long-term positive trend in the innovative drug sector, supported by China's growing capabilities in global competition and ongoing collaborations with multinational corporations [8][25][26]. - The medical device sector is showing signs of recovery, with leading companies reporting improved performance in Q3, indicating a potential influx of investment into this area [9][32]. Summary by Sections Industry Investment Rating - The industry is rated as "Outperform the Market" [2]. Recent Trends - The A-share pharmaceutical sector rose by 3.29% from November 10 to November 14, 2025, outperforming the CSI 300 index by 4.37 percentage points [7][23]. - The report notes that the medical device sector is expected to benefit from a reduction in the pressure from centralized procurement, which has been ongoing for six years [9][32]. Influenza and Related Products - The report indicates a rising trend in flu positivity rates in both southern and northern hospitals, with the southern region currently higher than the previous two years but lower than 2023 [6][16]. - Beneficiary stocks in the detection sector include companies like Innotec and Saint Shine, while traditional Chinese medicine companies such as Yiling Pharmaceutical are also highlighted [21]. Innovative Drugs - The report expresses optimism about the innovative drug sector, noting that domestic companies are expected to accelerate their growth and profitability, supported by favorable policies [25][26]. - Recommended stocks in this sector include Innovent Biologics and Kintor Pharmaceutical [27]. Medical Devices - The report suggests that the medical device sector is becoming attractive for investment, with leading companies like Mindray showing improved performance [9][32]. - Beneficiary stocks include Huadong Medicine and Aohua Endoscopy [33]. Traditional Chinese Medicine - The report indicates that traditional Chinese medicine is under pressure but may benefit from centralized procurement policies and innovation [36][38]. - Recommended stocks include Zhaoke Pharmaceutical and Kangyuan Pharmaceutical [36]. Retail Pharmacy - The report anticipates that the retail pharmacy sector will see increased concentration, with leading companies like Yifeng Pharmacy expected to benefit from market consolidation [39]. Overall Market Valuation - As of November 14, 2025, the overall valuation of the pharmaceutical sector is 30.83, with a premium of 129.30% over the CSI 300 index, indicating a positive market outlook [47].

Market Overview - Technology stocks experienced a collective pullback, with indices showing a slight V-shaped recovery [3] - The biodiesel sector saw significant gains, with stocks like Shanhigh Environmental and Jiaao Environmental hitting the daily limit [3] - Gene editing stocks surged, with companies such as Nanjing Xinbai and Jimin Health reaching their daily limits [3] - Oil service stocks also performed well, with companies like Zhun Oil and Shandong Molong hitting the daily limit [3] - The satellite internet sector saw a late-stage rally, with Shanghai Huguang and Shanghai Gangwan both experiencing sharp increases [3] Banking Sector - The banking sector showed resilience amidst the overall market decline, with major banks like Agricultural Bank of China leading the way [5] - Agricultural Bank of China saw a significant increase of 3.49%, reaching a market capitalization of over 3 trillion, solidifying its position as the second-largest bank globally [6] Satellite Internet - The satellite internet sector rebounded sharply in the late trading session, with notable gains from companies like Aerospace Zhizhuang and China Satellite [10] - The catalyst for this rally was the announcement of a new, cheaper Starlink home package by SpaceX, priced at $40 per month [10] Company-Specific Developments - Xingsen Technology experienced a rise of 6% after rumors of a partnership with Nvidia surfaced, although these claims were later disputed [12][13] - Daily Interaction saw a volatile trading session, initially declining but then surging over 10% due to speculation around a new product release related to DeepSeek [19]

Market Overview - The three major A-share indices collectively adjusted today, with the Shanghai Composite Index down 0.38%, the Shenzhen Component Index down 0.52%, and the ChiNext Index down 0.74% [1] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets was 12,680 billion yuan, a decrease of 1,864 billion yuan compared to the previous day [1] - Over 2,900 stocks in the market experienced an increase [1] Sector Performance - The sectors with the highest gains included cultivated diamonds, photovoltaic equipment, battery chemicals, gas, pharmaceutical commerce, and non-ferrous metals [1] - The sectors with the largest declines included coal mining and processing, insurance, liquor, AI corpus, computing power hardware, and securities [1] ETF Performance - In the ETF market, Hong Kong automotive ETFs showed strong performance, with gains of 2.38%, 2.35%, and 2.26% for Guangfa Fund, ICBC Credit Suisse Fund, and Huatai-PineBridge Fund respectively [1] - The new energy sector also performed well, with Penghua Fund's Science and Technology New Energy ETF rising by 1.94% [1] - Gold prices continued to rise, with Tianhong Fund's Shanghai Gold ETF increasing by 1.86% [1] - The coal sector saw significant declines, with the coal ETF down 2.56% [1] - The AI hardware sector weakened, with both the communication ETF and communication equipment ETF falling by 2% [1] - Consumer electronics concept stocks weakened, with the consumer electronics ETF down 1.63% [1]

Group 1 - The latest stock price of Shuyupingmin is 13.07 yuan, an increase of 0.22 yuan from the previous trading day's closing price, representing a rise of 1.71% [1] - The stock opened at 12.85 yuan, reached a high of 13.15 yuan, and a low of 12.81 yuan, with a trading volume of 51,659 hands and a transaction amount of 0.67 billion yuan [1] - Shuyupingmin operates in several concept sectors including pharmaceutical commerce, Shandong sector, medical beauty, cold chain logistics, and Shenzhen Stock Connect [1] Group 2 - The company primarily engages in the retail chain operation of pharmaceuticals, mainly selling drugs, medical devices, and health products [1] - Recent regulations regarding self-service medicine dispensing machines have raised industry concerns, with a draft proposal allowing these machines to dispense prescription drugs and Class A non-prescription drugs, leading to worries about changes in the competitive landscape [1] - Industry insiders noted that the operational costs of self-service dispensing machines are significantly lower than traditional pharmacies, which may disrupt existing retail pharmacy business models [1] Group 3 - There are differing opinions on the regulation of self-service dispensing machines, with some advocating for strict limitations to Class B non-prescription drugs, while prescription drug sales should continue to adhere to existing regulatory requirements [1] - On August 19, 2025, Shuyupingmin experienced a net outflow of 2.1911 million yuan in main funds, accounting for 0.07% of its circulating market value [1] - Over the past five days, the net outflow of main funds reached 17.4921 million yuan, representing 0.55% of its circulating market value [1]

Core Viewpoint - As of August 12, 2025, the stock price of Sely Medical closed at 29.18 yuan, reflecting a decline of 3.89% from the previous trading day, with a trading volume of 1.346 billion yuan and a turnover rate of 23.82% [1] Company Overview - Sely Medical's main business encompasses both the medical commercial and industrial sectors, with the commercial segment accounting for over 97% of its revenue [1] - The company is associated with several concept sectors, including pharmaceutical commerce, Hubei region, and biological vaccines [1] Shareholder Activity - On the evening of August 12, the company announced that its actual controller, Wen Wei, has fully released the pledge on 3 million shares. Following this release, the total pledged shares held by Wen Wei decreased to 5.3 million, representing 55.01% of his total holdings [1] Capital Flow - On August 12, Sely Medical experienced a net outflow of 206 million yuan in principal funds, which accounted for 3.7% of its circulating market value. Over the past five trading days, the cumulative net outflow reached 131 million yuan, representing 2.34% of its circulating market value [1]